title: Bone sarcomas as second malignant neoplasms following childhood cancer.
abstract: This study explores the relationship between histologic variants of bone sarcomas and previous therapy in patients in whom an unrelated malignant neoplasm had been diagnosed during childhood. Sarcomas of bone were the most common second malignant neoplasm (SMN) reported to the Late Effects Study Group, a 13-institution consortium consisting of pediatric oncology centers from western Europe, Canada, and the United States. The authors attempted to relate the histologic subtypes of the 91 bone tumors to clinical factors such as previous therapy and genetic predisposition because morphologic variants have been shown to have biologic significance in other tumors and may have etiologic import. The literature concerning the subtypes of bone tumors, clinical and experimental, is also reviewed. The authors also investigated the effect of several factors on the time interval from the first diagnosis to the SMN (i.e., the bone sarcoma). Anthracyclines significantly shortened the interval by about 3 years. The primary diagnosis also significantly affected the interval, with leukemia/lymphomas having the shortest interval and retinoblastoma the longest. The authors could not demonstrate any significant relationship between morphologic characteristics of the osteosarcoma and predisposing conditions. However, lesions diagnosed as chondrosarcoma and malignant fibrous histiocytoma occurred almost exclusively in patients who had received radiation therapy to the site in which the SMN developed.
authors.affiliation: Department of Pathology, Children's Hospital of Columbus, Ohio.
authors.forename: W A
authors.initials: WA
authors.lastname: Newton
authors.forename: A T
authors.initials: AT
authors.lastname: Meadows
authors.forename: H
authors.initials: H
authors.lastname: Shimada
authors.forename: G R
authors.initials: GR
authors.lastname: Bunin
authors.forename: G F
authors.initials: GF
authors.lastname: Vawter
mesh_terms: D000367:Age Factors; D000477:Alkylating Agents / Q000009:adverse effects; D000704:Analysis of Variance; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D001859:Bone Neoplasms / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D002648:Child; D005192:Family Health; D006801:Humans; D009381:Neoplasms, Radiation-Induced; D012516:Osteosarcoma / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D011878:Radiotherapy / Q000009:adverse effects; D012175:Retinoblastoma / Q000532:radiotherapy; D013997:Time Factors
chemical_list: D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic